Guggenheim analyst Seamus Fernandez lowered the firm’s price target on Eli Lilly to $392 from $395 and keeps a Buy rating on the shares. Flattening Mounjaro scripts, a "still generous coupon" and supply constraints suggest that sales are unlikely to beat consensus estimates in Q1, but continued strong double-digit overall GLP1 category growth points to Trulicity strength and Verzenio growth "continues to surprise to the upside," the analyst tells investors in a preview ahead of the company announcing Q1 results on Thursday, April 27.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on LLY:
- Eli Lilly price target raised to $448 from $444 at Morgan Stanley
- Weight-loss business upended by popularity of ozempic, other drugs, WSJ reports
- JPMorgan sees favorable risk/rewards for Eli Lilly, Biogen into data
- TD Cowen pharmaceuticals analysts to hold analyst/industry conference call
- Eli Lilly price target raised to $310 from $290 at Jefferies